Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator-Reference-Cited by-同舟云学术

Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator

Author:

Vella Adrian¹^ORCID,Freeman Jennifer L. R.²,Dunn Imogene²,Keller Kit²,Buse John B.³,Valcarce Carmen²

Affiliation:

1. Division of Endocrinology and Diabetes, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.

2. vTv Therapeutics Inc. and vTv Therapeutics LLC, High Point, NC 27265, USA.

3. Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.

Abstract

A hepatoselective glucokinase activator reduced hyperglycemia without hypoglycemia or adverse effects on lipids, liver enzymes, or blood pressure.

Funder

vTv Therapeutics LLC

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference50 articles.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献